Biofrontera Inc., a Delaware corporation, has announced a regulatory issue concerning its listing on The Nasdaq Capital Market. On May 8, 2025, the company received a notification from Nasdaq indicating non-compliance with Listing Rule 5550(a)(2) due to its common stock's closing bid price being below $1.00 per share for 33 consecutive business days. While this notice does not immediately affect the trading of Biofrontera's securities, the company has been granted a 180-day period, until November 5, 2025, to regain compliance by achieving a minimum closing bid price of $1.00 per share for at least 10 consecutive business days. If necessary, Biofrontera may seek additional time to rectify the issue, potentially through a reverse stock split. The company is actively monitoring the situation and exploring options to resolve the deficiency. However, there is no guarantee of regaining compliance or meeting other listing requirements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.